Highlights from the first day included updates from Exact Sciences about its plans for new tests slated for this year and ...

The recent clearance and a previous clearance together allow the use of Paige's FullFocus digital pathology image viewing software with scanners by Philips, Leica, and Hamamatsu.

The company said it expects Q4 2024 revenues of roughly $34.9 million, up from $31.5 million in Q4 2023 and above the consensus Wall Street estimate of $34.4 million.

NEW YORK – Pathology software developer Aiosyn said recently that it has gained CE marking for an algorithm that is used for mitotic figure counting in breast cancer diagnostics. The Nijmegen, ...

The government alleges Labcorp and UHS delayed submission of orders for tests by Caris Life Sciences to enable improper billings to Medicare for those tests.

The firm received notice that it had failed to regain compliance with the Nasdaq's requirement to maintain a minimum $35 million market value of listed securities.

NEW YORK – Anbio Biotechnology filed this week a preliminary prospectus for an initial public offering on the Nasdaq exchange of 1.6 million shares at an anticipated offering price in the range of $5 ...

The reagents are meant for measuring aCL and aβ2GP1 antibody levels in human serum to aid the diagnosis of primary and secondary APS.

Following OraSure's November 2024 lawsuit accusing NowDx of misappropriating trade secrets, NowDx has countersued OraSure over similar allegations.

Last week, readers were most interested in a story about the progress made by test developers toward commercializing rapid tests for sepsis.

The company received conditional approval from New York state for its new systemic lupus erythematosus and rheumatoid arthritis biomarker assays.

Numerous firms reported preliminary revenues along with other business updates on Sunday and Monday ahead of the annual JP Morgan Healthcare Conference.